최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Bulletin of the Korean chemical society, v.42 no.6, 2021년, pp.872 - 877
Lee, Yujin (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Jang, Jiyoon (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Bibi, Maimoona (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Duggirala, Krishna Babu (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Ji, Sang Hee (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Lee, Ji Hun (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Ahn, Sunjoo (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Song, Jin Sook (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Chae, Chong Hak (Bio and Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 34114 South Korea) , Kim, Seong Hwan (Bio and Drug Discovery Divis) , Lee, Kwangho
Apoptosis signal‐regulating kinase 1 (ASK1) is a member of mitogen‐activated protein kinase kinase kinase (MAP3K) family that involves downstream phosphorylation of MAP kinases, c‐Jun N‐terminal kinases, and p38 MAP kinases. ASK1 inhibitors could possibly be beneficial fo...
Matsuzawa, Atsushi, Saegusa, Kaoru, Noguchi, Takuya, Sadamitsu, Chiharu, Nishitoh, Hideki, Nagai, Shigenori, Koyasu, Shigeo, Matsumoto, Kunihiro, Takeda, Kohsuke, Ichijo, Hidenori. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nature immunology, vol.6, no.6, 587-592.
Ichijo, Hidenori, Nishida, Eisuke, Irie, Kenji, Dijke, Peter ten, Saitoh, Masao, Moriguchi, Tetsuo, Takagi, Minoru, Matsumoto, Kunihiro, Miyazono, Kohei, Gotoh, Yukiko. Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways. Science, vol.275, no.5296, 90-94.
J. Biol. Chem. Matsuzawa A. 1e8 130 2001
Kefala, Georgia, Tziomalos, Konstantinos. Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease. Expert review of gastroenterology & hepatology, vol.13, no.3, 189-191.
Chalasani, Naga, Younossi, Zobair, Lavine, Joel E., Diehl, Anna Mae, Brunt, Elizabeth M., Cusi, Kenneth, Charlton, Michael, Sanyal, Arun J.. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology : official journal of the American Association for the Study of Liver Diseases, vol.55, no.6, 2005-2023.
10.1111/j.1365-2036.2011.04724.x G.Vernon A.Baranova Z. M.Younossi Aliment Pharmacol. Ther.2011 34 274.
Zhang, Shiyan, Huang, Chaoying, Lyu, Xilin, Wang, Peipei, Zang, Yi, Wang, Zengtao, Wang, Huan, Li, Jia, Zhao, Yujun. Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1). European journal of medicinal chemistry, vol.195, 112277-.
Xin, Zhili, Himmelbauer, Martin K., Jones, J. Howard, Enyedy, Istvan, Gilfillan, Rab, Hesson, Thomas, King, Kristopher, Marcotte, Douglas J., Murugan, Paramasivam, Santoro, Joseph C., Gonzalez-Lopez de Turiso, Felix. Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors. ACS medicinal chemistry letters, vol.11, no.4, 485-490.
Lanier, Marion, Pickens, Jason, Bigi, Simone V., Bradshaw-Pierce, Erica L., Chambers, Alison, Cheruvallath, Zacharia S., Cole, Derek, Dougan, Douglas R., Ermolieff, Jacques, Gibson, Tony, Halkowycz, Petro, Hirokawa, Aki, Ivetac, Anthony, Miura, Joanne, Nunez, Evan, Sabat, Mark, Tyhonas, John, Wang, Haixia, Wang, Xiaolun, Swann, Steve. Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure. ACS medicinal chemistry letters, vol.8, no.3, 316-320.
Hou, Shaohua, Yang, Xiping, Tong, Yu, Yang, Yuejing, Chen, Quanwei, Wan, Boheng, Wei, Ran, Wang, Yuchen, Zhang, Yanmin, Kong, Bo, Huang, Jianhang, Chen, Yadong, Lu, Tao, Hu, Qinghua, Du, Ding. Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis. European journal of medicinal chemistry, vol.211, 113114-.
Harrison, Stephen A., Wong, Vincent Wai-Sun, Okanoue, Takeshi, Bzowej, Natalie, Vuppalanchi, Raj, Younes, Ziad, Kohli, Anita, Sarin, Shiv, Caldwell, Stephen H., Alkhouri, Naim, Shiffman, Mitchell L., Camargo, Marianne, Li, Georgia, Kersey, Kathryn, Jia, Catherine, Zhu, Yanni, Djedjos, C. Stephen, Subramanian, G. Mani, Myers, Robert P., Gunn, Nadege, Sheikh, Aasim, Anstee, Quentin M., Romero-Gomez, Manuel, Trauner, Michael, Goodman, Zachary, Lawitz, Eric J., Younossi, Zobair. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. Journal of hepatology : the journal of the European Association for the Study of the Liver, vol.73, no.1, 26-39.
Loomba, Rohit, Lawitz, Eric, Mantry, Parvez S., Jayakumar, Saumya, Caldwell, Stephen H., Arnold, Hays, Diehl, Anna Mae, Djedjos, C. Stephen, Han, Ling, Myers, Robert P., Subramanian, G. Mani, McHutchison, John G., Goodman, Zachary D., Afdhal, Nezam H., Charlton, Michael R.. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology : official journal of the American Association for the Study of Liver Diseases, vol.67, no.2, 549-559.
Clinical trials searched drug name “selonsertib”. URLhttps://clinicaltrials.gov/(accessed January 7 2021).
Terao, Y., Suzuki, H., Yoshikawa, M., Yashiro, H., Takekawa, S., Fujitani, Y., Okada, K., Inoue, Y., Yamamoto, Y., Nakagawa, H., Yao, S., Kawamoto, T., Uchikawa, O.. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorganic & medicinal chemistry letters, vol.22, no.24, 7326-7329.
N.Sakaiet al. (Takeda Pharmaceutical Company Limited) WO 2008/016192.
The biochemical activities against ASK1 were tested using the Eurofins Kinase Profiler screening platform (Eurofins Pharma Discovery Services UK Limited Dundee UK). In the assay ASK1 (h) is incubated with 8 mM MOPS pH 7.0 0.2 mM EDTA 0.33 mg/mL myelin basic protein 10 mM MgAcetate and [gamma‐33P]‐ATP. The reaction is initiated by the addition of the Mg/ATP mix. After incubation for 40 minutes at room temperature the reaction is stopped by the addition of phosphoric acid to a concentration of 0.5%. 10 μL of the reaction is then spotted onto a P30 filtermat and washed four times for 4 min in 0.425% phosphoric acid and once in methanol prior to drying and scintillation counting.
Schrödinger Release 2020‐4: Maestro 2020
Gomez-Lechon, M.J., Donato, M.T., Martinez-Romero, A., Jimenez, N., Castell, J.V., O'Connor, J.E.. A human hepatocellular in vitro model to investigate steatosis. Chemico-biological interactions, vol.165, no.2, 106-116.
Cellular TG content measurement.Human hepatoma cell line HepG2 (Korean Cell Line Bank Seoul Korea) were cultured in Minimal Essential Medium (MEM; HyClone Logan UT USA) with 10% fetal bovine serum (HyClone Logan UT USA) 1% antibiotic‐antimycotic solution (HyClone Logan UT USA) at 37°C and 5% CO2. Cells were incubated in a 96‐well plate at a density of 2 × 104cells/well for 24 h. Then cells were treated with compounds and/or the mixture of palmitic acid and oleic acid at a ratio of 1:2 that was incubated in water bath at 70°C for 30 min. After 2‐day incubation the cellular TG content was measured using Triglyceride Quantification Kit (Sigma‐Aldrich St. Louis MO USA).
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.